Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

15/10/2015 - 2 minutes

Minoryx Therapeutics is a Barcelona based Rare-disease specialist who has a panel of orphan-drug experts for their discovery program. Now backed in a €19.4M Series A round from leading VC firms Ysios (No 15 in our top EU VCs) and Roche Venture Fund, Minoryx will have the well-needed cash to push for further R&D of their pre-clinical candidate to treat a super rare X-linked neurodegenerative disorder.

Logo MinoryxMinoryx Therapeutics had only raised €5M since their founding in 2011. This dramatic series A fundraiser therefore indicates their research into developing new candidates for diseases of inborn errors of the metabolism (e.g. lysosomal storage disorders) has grown some real weight in their newly established VC syndicate. Minoryx’s pre-clinical candidate has indications for treatment of symptoms in rare CNS disorders -in particular the neurodegenerative X-ALD.

X-linked adrenoleukodystrophy (X-ALD) affects around 1 in 17,000 live births and is a congenital heterogenous disease which results in severe damage to the central nervous system (CNS).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!